Updated

Western biopharma companies are increasingly turning to China as a source of new drug innovation as the industry's "patent cliff" approaches. The shift reflects a strategy by major pharmaceutical firms to offset revenue losses from expiring patents by acquiring or licensing compounds developed in China's growing biotech ecosystem, reducing R&D timelines and costs.